IntelGenx Receives CIPO Notice of Allowance for Loxapine VersaFilm™ Patent

Published: Jul 05, 2018 By

SAINT LAURENT, Quebec, July 05, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) (“IntelGenx” or the “Company”), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform, today announced that the Canadian Intellectual Property Office (“CIPO”) recently issued a Notice of Allowance (“NoA”) for the Company’s Canadian Patent Application Number 2,998,223 entitled “Loxapine Film Oral Dosage Form”, covering the use of loxapine in an oral transmucosal film for the treatment of schizophrenia or bipolar 1 disorder. This is the Company’s first patent allowed in Canada and the Company’s first Canadian patent for its VersaFilm™ technology.

Upon issuance, the patent will grant exclusivity protection in Canada for IntelGenx’s Loxapine VersaFilm™ product for the treatment of schizophrenia or bipolar 1 disorder through 2037. This is also the Company’s first patent application to receive NoA in relation to its Loxapine VersaFilm™ project.

“This Notice of Allowance from CIPO is a significant development in our Loxapine VersaFilm™ project as it confirms our leading approach in developing oral films to provide patients with alternative oral treatment solutions,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.

About Loxapine VersaFilm™:

Loxapine VersaFilm™ is the first innovative oral thin film of loxapine for use in patients with agitation associated with schizophrenia and bipolar 1 disorder. Loxapine VersaFilm™ utilizes IntelGenx’s proprietary VersaFilm™ technology, allowing for an improved drug product which addresses unmet medical needs in schizophrenia and bipolar 1 disorder.

Agitation associated with schizophrenia or bipolar mania is not uncommon and can rapidly escalate into physically aggressive behavior that can be potentially dangerous to the agitated individual and others if left untreated. In a clinical setting, agitation associated with schizophrenia and bipolar mania are often effectively managed with behavioral and psychological techniques, with unexpected acute agitation typically being treated with parenterally administered sedatives such as benzodiazepines and/or antipsychotic drugs such as olanzapine and ziprasidone.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx’s annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

Contacts :

Stephen Kilmer
Investor Relations 
(514) 331-7440 ext. 232
stephen@intelgenx.com

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext. 203
andre@intelgenx.com

Primary Logo

Back to news